Form 4: Immunome Director Jean-Jacques Bienaime Receives Options

Immunome, Inc. director Jean-Jacques Bienaime was granted 9,897 stock options as part of his compensation package.

Summary

• Director Jean-Jacques Bienaime received a grant of 9,897 stock options on June 10, 2026.
• The options have an exercise price of $18.16 per share.
• The options are set to expire on June 9, 2036.
• Vesting occurs in four equal quarterly installments over one year, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding director compensation, which carries no significant signal regarding company performance.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is subject to the director's continuous service with the company.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure alignment between leadership and shareholders, particularly for companies in the development stage.

Comparison to Industry Standards

• The use of quarterly vesting over one year is a standard retention mechanism for board members in the life sciences industry.
• The grant size is consistent with typical non-employee director compensation packages for small-cap biotech firms.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first installment of options on September 10, 2026.

Key Dates

Keywords

Immunome, IMNM, Form 4, Insider Trading, Stock Options, Director Compensation